3rd Quarter - Report
FORBES-TATE for ALEXION PHARMACEUTICALS, INC.
Firm
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| JERRY DRISCOLL | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
| ZACHARY WILLIAMS | — |
Medicare/Medicaid MMM
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CYNTHIA BROWN | — |
| JERRY DRISCOLL | — |
| JEFFREY FORBES | — |
| ELIZABETH GREER | — |
| DERRICK M WHITE | — |
| MICHAEL ALEXANDER WILLIAMS | — |
| ZACHARY WILLIAMS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.